Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | CASR | P41180 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MITF | O75030 | 2/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158936 | 0.87 | NPC1 (0.60) | ALDH1A1NPC1RAB9ACASRSMN1; SMN2 | |
| SCHEMBL27519540 | 0.85 | ALDH1A1 (0.82) | ALDH1A1NPC1RAB9ACASRSMN1; SMN2 | |
| SCHEMBL6915485 | 0.84 | ALDH1A1 (0.60) | ALDH1A1EPHX2PTPN7NAMPTMAPT | |
| SCHEMBL6064770 | 0.80 | CASR (0.64) | ALDH1A1NPC1RAB9ACASRSMN1; SMN2 | |
| SCHEMBL30443967 | 0.80 | CASR (0.63) | ALDH1A1NPC1RAB9ACASRSMN1; SMN2 | |
| SCHEMBL8625971 | 0.79 | ALDH1A1 (0.52) | ALDH1A1PAX8EPHX2PTPN7NAMPT | |
| SCHEMBL7837395 | 0.79 | NAMPT (0.53) | ALDH1A1NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL10658594 | 0.78 | LMNA (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL7158245 | 0.78 | EPHX1 (0.72) | ALDH1A1CASREPHX2NR1H4 | |
| SCHEMBL7414814 | 0.78 | ALDH1A1 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9050339-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2616447-B1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-02-18 | — | — | EP | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885NPC1 2495/4885RAB9A 233/4885 |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885NPC1 2495/4885RAB9A 233/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885NPC1 2495/4885RAB9A 233/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885NPC1 2495/4885RAB9A 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.